|Day Low/High||78.83 / 80.86|
|52 Wk Low/High||65.25 / 92.64|
If there was not a sizable addressable market for Beyond Meat, the competition would not be building as quickly as it is.
Despite the rhetoric from on high, it is possible to find good stock picks in this market.
The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.
A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.
We don't have enough stock pickers or individuals to handle all the new stock that's been created. And It is trashing the cloud kings, among others.
The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
There are plenty of senior growth companies that can still move higher.
Let me give you the items I want to see before I bless buying anything in what has become a plain, out and out, treacherous market.
When you have an oversold market you've got a true coiled spring that can rally beyond where it might ordinary go on good news.
Let's visit with the charts and indicators to get another perspective.
Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.
In my opinion, MA is a good one, otherwise it would not be on my book.
These three names - GD, MRK, WMT - will either hit resistance or hurdle immediate pivot points in as traders (or bots) try to form a technical breakout.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.
Kimberly-Clark's performance is nothing to sneeze at, and neither is Coca-Cola's, as higher sales, higher prices and big demand from emerging markets appear to give us a return to the good old days of great senior growth stocks.
Here are my five rules for handling earnings season.
Let's see if either of these names provide an entry this week.
Here's an updated strategy.
I am neutral on this market, and only a cool off of the hottest stocks can justify a further advance.
Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.
This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
The names include a veterinary drug concern plus companies with successful drugs on the market.